EUVIMEDEUVIMED entdecken
Crossref

Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study

Michael Hardy, Henri Thonon, Jonathan Douxfils, Julie Vassart, Isabelle Gouin-Thibault, Sarah Lessire, Thomas Lecompte, François Mullier

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2025.06.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Michael Hardy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Recherche Expérimentale et Clinique (IREC)-Pôle Mont, Université catholique de Louvain, Louvain-la-Neuve, Belgium; CHU UCL Namur, Departm…. Hauptthemen laut MEDLINE: Thrombin, Heparin, Platelet-Rich Plasma, Anticoagulants. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Fund for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Invasive endovascular procedures often require anticoagulation to prevent device-associated thrombosis. High doses of unfractionated heparin (UFH) are the gold standard. The efficacy of factor (F)XII(a) and FXI(a) inhibitors remains unexplored. OBJECTIVES: We aimed to investigate, using a validated in vitro model of catheter-initiated thrombin generation (TG) in platelet-rich plasma (PRP), the effects of garadacimab, abelacimab, asundexian, and milvexian and of commonly used anticoagulants apixaban, dabigatran, fondaparinux and heparins (enoxaparin and UFH). METHODS: Anticoagulants were added to PRP at 6 concentrations and effects compared with UFH as a reference. The impact of adding anticoagulants into collection tubes before most preanalytical contact activation was also assessed. Concentrations achieving a 50% reduction in TG peak height (PH) were determined (IC50). RESULTS: All anticoagulants prolonged lag time (LT) and reduced PH and endogenous thrombin potential, albeit to varying extents. UFH was the only anticoagulant able to suppress TG at clinically achieved concentrations (1 U/mL). The following IC50 were found: milvexian, 2400 ng/mL; apixaban and dabigatran, 175 ng/mL; fondaparinux, 2.4 μg/mL; enoxaparin, 0.5 U/mL; and UFH, 0.25 U/mL. Asundexian up to 5000 ng/mL failed to reduce TG PH by 50%. Adding garadacimab and abelacimab to collection tubes resulted in greater efficacy than when added to PRP: LT increased by 89% and 32%, respectively; IC50 were 25 and 12.5 μg/mL, respectively. CONCLUSION: Heparins were by far the most effective anticoagulants in our in vitro model. FXIIa and FXI(a) inhibitors did not adequately prevent coagulation on the studied artificial surface. Direct oral anticoagulants and fondaparinux showed limited efficacy, aligning with clinical observations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombinHeparinPlatelet-Rich PlasmaAnticoagulantsFactor XIIFactor XIBlood CoagulationHumansAdministration, OralFactor Xa Inhibitors

Stichwörter der Autor:innen

catheterdirect oral anticoagulantsfactor XI inhibitorsheparinthrombin generation

Substanzen

ThrombinHeparinAnticoagulantsFactor XIIFactor XIFactor Xa Inhibitors

Autor:innen und Institutionen

  • Institut de Recherche Expérimentale et Clinique (IREC)-Pôle Mont, Université catholique de Louvain, Louvain-la-Neuve, Belgium; CHU UCL Namur, Department of Laboratory Medicine, Namur Thrombosis and Hemostasis Center (NT…
  • University of Namur, Pharmacy Department, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Namur, Belgium; Qualiblood SA, Namur, Belgium.
  • University of Namur, Pharmacy Department, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Namur, Belgium.
  • Department of Laboratory Medicine, Pontchaillou University Hospital of Rennes, Rennes, France.
  • Institut de Recherche Expérimentale et Clinique (IREC)-Pôle Mont, Université catholique de Louvain, Louvain-la-Neuve, Belgium; CHU UCL Namur, Blood Transfusion Center, Yvoir, Belgium.
  • University of Namur, Pharmacy Department, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Namur, Belgium; University Hospital of Nancy, Vascular Medicine Department,…

Förderung

  • Fund for Scientific Research

Zitieren

APA

Hardy, M., Thonon, H., Douxfils, J., Vassart, J., Gouin-Thibault, I., Lessire, S., Lecompte, T., & Mullier, F. (2025). Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.06.016

Vancouver

Hardy M, Thonon H, Douxfils J, Vassart J, Gouin-Thibault I, Lessire S, et al. Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.06.016

BibTeX
@article{Hardy2025,
  author = {Hardy, Michael and Thonon, Henri and Douxfils, Jonathan and Vassart, Julie and Gouin-Thibault, Isabelle and Lessire, Sarah and Lecompte, Thomas and Mullier, François},
  title = {Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2025.06.016}
}
Kostenlos starten →